AccuLine Secures $4.2 Million in Seed Funding to Revolutionize CAD Detection and Save Lives Globally

AccuLine, a pioneering company focused on saving lives through early detection of heart conditions, has successfully raised $4.2 million in funding. The company's innovative solution, CORA, offers a non-invasive and accurate examination for the early detection of coronary artery disease (CAD). This funding round will be instrumental in further developing and promoting CORA, which aims to replace outdated and inefficient ergometry exams with a quick and reliable four-minute vital sign measurement. With a strong backing from notable entities like Google and the Israeli Innovation Authority, as well as support from shareholders such as Mayo Clinic and Maccabi Healthcare Services, AccuLine is well-positioned to revolutionize the field of cardiac health monitoring. The end goal is clear: to make early detection of heart issues more accessible, affordable, and effective, ultimately saving lives across the globe.